x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0011902
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG |
| Host Species | Rabbit |
| Reactivity | Human, Mouse, Rat |
| Applications | WB |
| Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Phe292 of human CIAO1 protein. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | CIAO1 |
| UniProt No. | O76071 |
| Gene ID | 9391 |
| Gene Description | Iron-sulfur clusters are cofactors for many proteins that display a wide range of biological functions, such as DNA maintenance, transcription, translation, cellular metabolism, electron transport, and oxidative phosphorylation. While structurally simple, the synthesis and insertion of ISC into Fe-S proteins are complex processes that involve many different proteins. The cytosolic iron-sulfur assembly component 1 protein is a key component of the cytosolic ISC assembly machinery that incorporates ISC into cytoplasmic and nuclear Fe-S proteins in eukaryotic cells. CIAO1, along with MMS19, XPD, FAM96B, and ANT2, comprise a complex that localizes to the mitotic spindle during mitosis, which suggests a role in chromosome segregation. The CIAO1 protein interacts with Wilms' tumor suppressor protein and may affect its transactivation activity. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
